Dianthus Therapeutics

Dianthus Therapeutics

Yahoo Finance • last month

Stocks Settle Sharply Lower on Escalating Middle East Tensions

The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.87%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.98%.  June E-mini S&P futures (ESM26) fell -1.62%, and... Full story

Yahoo Finance • last month

Stocks Resume Decline as Chipmakers and AI Companies Fall

The S&P 500 Index ($SPX) (SPY) today is down -0.61%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.88%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.80%.  June E-mini S&P futures (ESM26) are down -0.71%, and June E-mini Na... Full story

Yahoo Finance • last month

Stocks Fall on Weakness in Tech and Trucking Companies

The S&P 500 Index ($SPX) (SPY) today is down -0.28%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.38%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.28%.  June E-mini S&P futures (ESM26) are down -0.25%, and June E-mini Na... Full story

Yahoo Finance • last month

Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK

The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $... Full story

Yahoo Finance • last month

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline

Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 7, Raymond James increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) from $123 to $125.... Full story

Yahoo Finance • 2 months ago

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Octagon Capital Advisors cut its stake in Dianthus Therapeutics(NASDAQ:DNTH) by 470,000 shares, an estimated $27.22 million trade based on quarterly average pricing, according to a May 15, 2026 SEC filing. What happened According to a SE... Full story

Yahoo Finance • 2 months ago

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally

On May 15, 2026, Cormorant Asset Management disclosed a new position in Dianthus Therapeutics(NASDAQ:DNTH), acquiring 950,000 shares in an estimated $55.01 million trade based on quarterly average pricing. What happened According to a Se... Full story

Yahoo Finance • 2 months ago

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 mill... Full story

Yahoo Finance • 2 months ago

LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis

NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's dise... Full story

Yahoo Finance • 3 months ago

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000

Key Points 8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share. This transaction represented 100.00% of Mr. Savitz's direct common stock holdings, reducing his direct... Full story

Yahoo Finance • 3 months ago

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe aut... Full story

Yahoo Finance • 4 months ago

Dianthus rises as FDA agrees with proposed changes to lead program

[FDA Headquarters] Shares of Dianthus Therapeutics (DNTH [https://seekingalpha.com/symbol/DNTH]) spiked on Thursday after the company announced that the FDA agreed with several proposed changes related to clinical development of its lead... Full story

Yahoo Finance • 4 months ago

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position... Full story

Yahoo Finance • 4 months ago

Dianthus Prices $625 Mln Offering To Advance Claseprubart And Broader Autoimmune Pipeline; Stock Up

(RTTNews) - Dianthus Therapeutics, Inc. (DNTH) has priced an upsized $625 million underwritten public offering as the clinical-stage biotech prepares to advance multiple programs targeting severe autoimmune and neuromuscular diseases. The... Full story

Yahoo Finance • 4 months ago

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transfo... Full story

Yahoo Finance • 4 months ago

Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)

Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 4, Guggenheim increased the price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $200 from $100. The fi... Full story

Yahoo Finance • 4 months ago

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe aut... Full story

Yahoo Finance • 8 months ago

Dianthus Therapeutics GAAP EPS of -$0.97

* Dianthus Therapeutics press release [https://seekingalpha.com/pr/20295274-dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-financial] (DNTH [https://seekingalpha.com/symbol/DNTH]): Q3 GAAP EPS of -$0.97. *... Full story

Yahoo Finance • 8 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy measures at Week 13 in Phase 2 MaGic... Full story

Yahoo Finance • 8 months ago

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase 3 gMG trial planned to include QMG ≥10... Full story